ProQR to Present RNA Therapy Data at Upcoming Conferences
The company will detail clinical and preclinical progress for its AI-designed RNA editing candidates starting November 3.
Updated on Oct. 28, 2026 in Biotech
Live Poll
Should pharmaceutical companies prioritize AI-driven development to accelerate the discovery of new medical treatments?
ProQR Therapeutics plans to share new clinical and preclinical data for its RNA editing therapies AX-0810 and AX-0811 across three international scientific conferences starting November 3, 2026. These presentations cover the company's Axiomer platform, which utilizes endogenous ADAR enzymes to modify RNA sequences.
Why it matters
As the industry shifts toward programmable RNA medicine, these data releases provide an early look at the efficacy and durability of synthetic oligonucleotides designed to modulate disease-driving protein expression.
The Axiomer platform recruits endogenous ADAR to convert Adenosine to Inosine, correcting mutations or modulating protein levels. The AX-0811 candidate, designed via an AI-enabled discovery engine, shows improved performance over its predecessors.
The players
ProQR Therapeutics
A clinical-stage biotechnology company based in Leiden, Netherlands, focused on RNA editing platforms for genetic and metabolic diseases.
The details
ProQR Therapeutics uses Axiomer RNA editing oligonucleotides to direct endogenous ADAR — an enzyme naturally present in cells — to perform site-specific base editing. By changing Adenosine to Inosine, the therapy can either correct genetic mutations back to their functional wild-type state or alter protein expression levels. AX-0810 is specifically engineered to modulate bile acid transport in cholestatic disease, while AX-0811 targets NTCP — a protein transporter found in the liver — using a more potent architecture discovered through AI-driven modeling.
Timeline
November 3, 2026: Plenary presentation at TIDES Europe in Amsterdam.
November 5-9, 2026: The Liver Meeting 2026 in Denver, CO.
December 9, 2026: Presentation at Nature Conferences RNA in La Jolla, California.
January 2027: Expected initial data for the AX-0811 Phase 1 study.
The Tech Race
ProQR Therapeutics is advancing its Axiomer platform to compete with established gene-editing modalities by leveraging endogenous enzymes rather than introducing foreign protein machinery. This shift represents a transition from broad-acting therapeutics to highly specific, programmable RNA modulation.
The potential clinical utility of these therapies will remain speculative until the Phase 1 trial results for AX-0811 emerge in early 2027. Future treatment availability depends on the outcome of these initial human studies and subsequent regulatory review.
The takeaway
ProQR is attempting to validate its AI-enabled RNA editing engine against the stringent requirements of clinical translation. Watch for the Phase 1 trial results in January 2027 to see if human safety and potency metrics align with the durability observed in earlier preclinical work.
Further reading
Explore the latest shifts in Biotech to understand how RNA editing is evolving beyond standard gene therapy.
Source note: This article includes information reported by The Manila times.
Live Poll
Should pharmaceutical companies prioritize AI-driven development to accelerate the discovery of new medical treatments?
